NCT06037018View on ClinicalTrials.gov

Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies

PHASE1RecruitingINTERVENTIONAL

Enrollment

44

Participants

Timeline

Start Date

August 7, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

Non-hodgkin LymphomaAcute Lymphoblastic LeukaemiaChronic Lymphocytic Leukemia

Interventions

BIOLOGICAL

CC312

Doses from 0.3 to 45 µg/dose by intravenous infusion

Trial Locations (1)

300020

RECRUITING

InstituteHBDH, Tianjin

Sponsors

Lead Sponsor

All Listed Sponsors

lead

CytoCares Inc

INDUSTRY